Febuxostat (Urica) was studied in healthy subjects in doses up to 300 mg daily for 7 days without evidence of dose-limiting toxicities. No overdose of Febuxostat was reported in clinical studies. Patients should be managed by symptomatic and supportive care when overdose occurs.